News | November 06, 2025
Zydus wellness reports 31% growth in net sales in Q2 FY26
During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries
During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
The ALLEGORY study demonstrated statistically significant improvements in key measures, including British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response
Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
INEOS production of BDO in Germany, which produces a vital ingredient for antibiotics, statins and vitamin B6, is being crushed by a flood of carbon heavy imports and product dumping from the Far East
OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Subscribe To Our Newsletter & Stay Updated
